Tag: FDA

Novartis logo

Breaking News: FDA Approves Treatment for pNET Patients

May 5, 2011

For the first time in nearly three decades, there is a new treatment for pancreatic neuroendocrine tumor patients!  The Food and Drug Administration (FDA) today announced its approval of Afinitor© for pNET patients.  This is a milestone for the carcinoid/NET…

READ MORE
FDA logo

Carcinoid Cancer Foundation to Speak on Behalf of NET Cancer Patients at April 12, 2011 FDA Oncologic Drugs Advisory Committee Meeting

March 24, 2011

Grace Goldstein, Chief Operating Officer of the Carcinoid Cancer Foundation, will speak at the Open Public Hearing segment during the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee Meeting on April 12, 2011 in Silver …

READ MORE
glucomedix1

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

March 23, 2011

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim

READ MORE
arthur t sands md phd president and chief executive officer lexicon pharmaceuticals5

Lexicon Pharmaceuticals, Inc. Clinical Trial Recruiting Carcinoid Syndrome Patients

September 10, 2010

Patients with carcinoid syndrome, whose symptoms are not managed by octreotide therapy, are being recruited for a Phase 2 clinical trial of Lexicon Pharmaceuticals’ LX1606 (a.k.a. LX1032).  The trial has been given Fast Track status in the U.S. and …

READ MORE
ebrahim s delpassand md facnm

FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)

August 24, 2010

For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…

READ MORE